

AACR 2024 Annual Meeting: Ludwig Community Poster Sessions

Poster session date	Session title	Session type - Location	Poster title	Ludwig location	Presenter/Ludwig PI	Session time (U.S. EDT)
4/7/2024	Session PO.IM02.07 - Tumor-Induced Immune Suppression 1: Extrinsic Factors	Section 4	109 / 13 - Identification of tumor-intrinsic and extrinsic mechanisms of T cell exclusion in estrogen receptor-positive (ER+) breast cancer through integration of bulk and single-cell transcriptome and spatial analysis	Ludwig Harvard	Kenichi Shimada/Guerriero Lab	1:30 PM - 5:00 PM
4/7/2024	Session PO.MCB04.01 - Cellular Stress Responses 1	Section 16	377 / 9 - Saturation mutagenesis of KEAP1 to identify pathogenic mutations in lung cancer patients and gain insight into KEAP1 molecular function	Ludwig Stanford	Noah Kastelowitz/Diehn Lab	1:30 PM - 5:00 PM
4/7/2024	PO.MCB09.01 - Metabolic Pathways 1	Section 18	433 / 11 - BCAT1 promotes HCC metabolic reprogramming and survival through HIF-1 α stabilization	Scholar-in-Training Award (Travel Award) Recipient	Kenneth Kin Leung Kwan	1:30 PM - 5:00 PM
4/8/2024	Session PO.CT01.04 - Phase I Clinical Trials 1	Section 48	CT052 / 2 - A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer	Ludwig Institute	N/A	9:00 AM - 12:30 PM
4/8/2024	PO.CL02.01 - Biostatistics in Clinical Trials / Surgical Oncology	Section 39	2392 / 7 Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab	Ludwig Harvard	Christopher Graser/Michor Lab	9:00 AM - 12:30 PM
4/8/2024	PO.CL01.07 - Predictive Biomarkers 1	Section 43	2489 / 6 A cell-free DNA methylation biomarker outperforms irRECIST in predicting treatment outcome	Ludwig Oxford	Benjamin Schuster-Böckler	9:00 AM - 12:30 PM
4/8/2024	PO.CL13.02 - Translational Research: Imaging and Radiomics	Section 46	2593 / 20 Spatial multi-omics profiling of tumor cell phenotypes in primary cutaneous melanoma at single-cell resolution	Ludwig Harvard	Tuulia Vallius/Sorger Lab	9:00 AM - 12:30 PM
4/8/2024	PO.ET09.06 - Novel Targets and Pathways	Section 29	2082 / 6 Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape	Ludwig Johns Hopkins	Nick Wyhs/Kinzler-Vogelstein Lab	9:00 AM - 12:30 PM
4/8/2024	PO.TB11.07 - Immune Cells in the Tumor Microenvironment 1	Section 9	1521 / 8 Chromatin remodeler ACTL6A in CD8+ T cells promotes antitumor immunity	Ludwig Harvard	Bogang Wu/Ellisen Lab	9:00 AM - 12:30 PM

4/8/2024	PO.PR02.01 - Role of Diet, Nutrition, and the Microbiome Across the Cancer Continuum	Section 32	2179 / 13 - Microbiome-derived metabolites mediate carcinogenic alterations of breast tissue in the context of obesity	Scholar-in-Training Award (Travel Award) Recipient	Mohamed Gaber	9:00 AM - 12:30 PM
4/8/2024	PO.PR02.01 - Role of Diet, Nutrition, and the Microbiome Across the Cancer Continuum	Section 32	2168 / 2 - Intermittent fasting in combination with carboplatin in a pre-clinical model of obesity-driven endometrial cancer	Scholar-in-Training Award (Travel Award) Recipient	Jennifer Haag	9:00 AM - 12:30 PM
4/8/2024	PO.TB07.01 - Radiation Science	Section 12	2874 / 5 Cancer metabolism in radiation resistance: Complementary roles of O-GlcNAc transferase and PARP1	Ludwig Chicago	Stephen Kron	1:30 PM - 5:00 PM
4/8/2024	PO.ET03.02 - Mechanisms of Drug Resistance 2	Section 26	3289 / 29 APOBEC3A drives tumor evolution through activation of ERVs in non small cell lung cancer	Ludwig Harvard	Hideko Isozaki/Hata Lab	1:30 PM - 5:00 PM
4/8/2024	PO.MCB11.01 New Insights into Tumor Suppressor Genes	Section 17	3015 / 13 HD-PTP mediates tumor suppression via modulation of anti-tumor immunity	Ludwig Harvard	Chenxu Guo/Ellisen Lab	1:30 PM - 5:00 PM
4/8/2024	PO.MCB11.01 New Insights into Tumor Suppressor Genes	Section 17	3024 / 22 HIF1A and HIF2A differentially contribute to early and adaptive changes following in vivo Vhl inactivation in the kidney	Ludwig Oxford	Samvid Kurlekar/Ratcliffe Lab	1:30 PM - 5:00 PM
4/8/2024	PO.MCB09.04 - Signaling Pathways That Regulate Metabolism 1	Section 19	3063 / 3 - Defining oncogene-specific metabolic vulnerabilities in a mouse model of hepatocellular carcinoma	Scholar-in-Training Award (Travel Award) Recipient	Kamal Al-Shami	1:30 PM - 5:00 PM
4/9/2024	PO.ET06.04 Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes	Section 26	4644 / 20 Single strand DNA GAP accumulation as a functional biomarker for USP1 inhibitor sensitivity in ovarian cancer patient-derived organoid models	Ludwig Harvard	Alexandre Da Costa/D'Andrea Lab	9:00 AM - 12:30 PM
4/9/2024	PO.IM01.04 Combination Approaches	Section 3	4034 / 10 Lag3 blockade enhances the anti-tumor effect of dual GITR agonism and PD-1 blockade in a preclinical melanoma model	Ludwig Weill Cornell	Rachana Maniyar/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM
4/9/2024	PO.IM01.04 Combination Approaches	Section 3	4051 / 27 Optimizing breast cancer therapy by modulating oxygen consumption	Ludwig Weill Cornell	Anaïs Assouvie/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM
4/9/2024	PO.IM01.04 Combination Approaches	Section 3	4052 / 28 Neutrophil recruitment and activation promotes cutaneous adverse effects with T cell immunotherapies	Ludwig Weill Cornell	Daniel Hirschhorn/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM
4/9/2024	PO.IM01.04 Combination Approaches	Section 3	4053 / 29 Targeting oxygen consumption with metformin and phenformin have differential effects on immune cells in the tumor microenvironment	Ludwig Weill Cornell	Sadna Budhu/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM

4/9/2024	PO.IM01.08 Vaccines, Antigens, and Antigen Presentation 1	Section 5	4090 / 1 Gut microbiota mimics as a source of cross-reactive tumor rejection antigens	Ludwig Weill Cornell	Vincent Panneton/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM
4/9/2024	PO.IM01.08 Vaccines, Antigens, and Antigen Presentation 1	Section 5	4093 / 4 Modeling tumor immunoediting under immune selective pressure to inform neoantigen landscape dynamics for effective cancer vaccines	Ludwig Weill Cornell	Mariam Matthew George/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM
4/9/2024	PO.MCB09.03 Metabolomics	Section 18	4425 / 5 Metabolic vulnerabilities of dedifferentiated liposarcoma	Ludwig Harvard	Jamie Brett/Haigis Lab	9:00 AM - 12:30 PM
4/9/2024	LBPO.TB02 Late-Breaking Research: Tumor Biology 2	Section 54	LB311 / 6 Multimodal spatial profiling reveals the emergence of an immune suppressive microenvironment at the initial stages of high-grade serous ovarian cancer development	Ludwig Harvard	Tanjina Kader/Sorger-Santagata Lab	9:00 AM - 12:30 PM
4/9/2024	PO.CT02.01 Phase II Clinical Trials 1	Section 49	CT208 / 8 High tumor monocyte content predicts long-term survival for patients with operable oesophageal cancer treated with neoadjuvant immunochemotherapy in the LUD2015-005 trial	Ludwig Oxford	Hannah Fuchs/Lu Lab	9:00 AM - 12:30 PM
4/9/2024	PO.PR01.04 - Health Disparities Across the Cancer Continuum	Section 31	2153 / 20 - The impact of socioeconomic and racial segregation on cancer stage at diagnosis, treatment and mortality among patients with small cell lung cancer	Scholar-in-Training Award (Travel Award) Recipient	Bayu Bekele	9:00 AM - 12:30 PM
4/9/2024	PO.CL06.02 Adoptive Cellular Therapy 2	Section 40	6325 / 16 Lineage tracing defines responding CAR T cells in patients with B cell malignancies	Ludwig Stanford	Zinaida Good/Mackall Lab	1:30 PM - 5:00 PM
4/9/2024	PO.EN01.02 Molecular, Preclinical, and Clinical Endocrinology 2	Section 38	6285 / 24 Defining androgen receptor function and the effects of PARP inhibition in BRCA1/2-deficient vs. proficient prostate cancer	Ludwig Harvard	Nicole Traphagen/Brown Lab	1:30 PM - 5:00 PM
4/9/2024	PO.ET03.03 Mechanisms of Drug Resistance 3	Section 24	5858 / 2 Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer	Ludwig Harvard	Bogang Wu/Ellisen Lab	1:30 PM - 5:00 PM
4/9/2024	PO.ET03.07 Drug Resistance 3: Regulation of Gene Expression	Section 23	5850 / 26 Multiomics analysis unravels tumor metabolic reprogramming and potential resistance mechanism(s) to curative therapy in TNBC	Ludwig Harvard	Zuen Ren/Ellisen Lab	1:30 PM - 5:00 PM
4/9/2024	PO.ET03.07 Drug Resistance 3: Regulation of Gene Expression	Section 23	5825 / 1 Non-genetic determinants driving the evolutionary trajectories of drug-tolerant-persisters in KRAS Non-small cell lung cancer	Ludwig Harvard	Chendi Li/Hata Lab	1:30 PM - 5:00 PM
4/9/2024	PO.MCB10.03 microRNAs and Other Non-coding RNAs as Cancer Genes 2	Section 17	5689 / 10 miR-21: A therapeutic target that delays severe liver disease and hepatocellular carcinoma under high-fat-diet conditions	Ludwig Harvard	Urmila Jagtap/Slack Lab	1:30 PM - 5:00 PM

4/9/2024	PO.PS01.01 - Genetic Epidemiology 1: GxE, GWAS, and Next-Generation Sequencing	Section 33	6145 / 7 - A trans-ethnic meta-analysis identified additional novel genomic loci associated with cervical cancer	Scholar-in-Training Award (Travel Award) Recipient	Abram Bunya Kamiza	1:30 PM - 5:00 PM
4/10/2024	PO.CL06.03 Cancer Immunity and Inflammation	Section 40	7472 / 15 Melanoma-intrinsic expression of signal-regulatory protein alpha (SIRP α) confers tumor cells resistance to anti-tumor adaptive immunity	Ludwig Weill Cornell	Chien-Huan Weng/Wolchok-Merghoub Lab	9:00 AM - 12:30 PM
4/10/2024	PO.ET06.02 DNA Damage and Repair	Section 22	7120 / 15 Investigating PARP1 selective inhibitor DSB1559 efficacy in BRCA1-associated triple negative breast cancer	Ludwig Harvard	Adam Nelson/Guerriero Lab	9:00 AM - 12:30 PM
4/10/2024	PO.TB10.01 Tumor Evolution at Single Cell Resolution	Section 11	6944 / 22 Transcriptional programs underpinning reoccurring cancer cell states, plasticity and tumour phylogenies in clear cell kidney cancer	Ludwig Oxford	Olivia Lombardi/Ratcliffe Lab	9:00 AM - 12:30 PM